NCT05696028

Brief Summary

Comparison of different Gfr measurements in Chronic Kidney Diseases

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
166

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2023

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 28, 2022

Completed
28 days until next milestone

First Posted

Study publicly available on registry

January 25, 2023

Completed
7 days until next milestone

Study Start

First participant enrolled

February 1, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

January 25, 2023

Status Verified

January 1, 2023

Enrollment Period

7 months

First QC Date

December 28, 2022

Last Update Submit

January 13, 2023

Conditions

Chronic Kidney Diseases

Outcome Measures

Primary Outcomes (1)

  • Is to Compare gfr measured by radionuclide method to gfr measured by creatinine clearance in patients with CKD

    Gfr can be measured by quantification of plasma and standard volume sample using a quality controlled gamma\_counter and Gamma camera these techniques the central assumption that the tracer is cleared solely by glomerular filtration.

    1year

Interventions

Gamma counterDEVICE

DTpA

Also known as: Radionucide method

Eligibility Criteria

Age40 Years - 60 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients proven or suspected CKD

You may qualify if:

  • patients with proven or suspected CKD who will be referred to nuclear medicine departement of Assuit University hospital and will undergo dynamic renal imaging.

You may not qualify if:

  • Severely ill patients
  • Disturbed conscious level
  • Patients on dialysis
  • patients have oedema or ascites

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Asmaa Zidan, doctor

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Asmaa Zidan, doctor

CONTACT

01094828826Zasmaa650@gmail.com

Randa El Zohne, doctor

CONTACT

01003390690randaelzohne@yahoo.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor at clinical pathology departement

Study Record Dates

First Submitted

December 28, 2022

First Posted

January 25, 2023

Study Start

February 1, 2023

Primary Completion

September 1, 2023

Study Completion

December 1, 2023

Last Updated

January 25, 2023

Record last verified: 2023-01